NATCO Pharma Limited
NATCO Pharma Limited Fundamental Analysis
NATCO Pharma Limited (NATCOPHARM.BO) shows strong financial fundamentals with a PE ratio of 11.25, profit margin of 34.13%, and ROE of 20.08%. The company generates $45.6B in annual revenue with strong year-over-year growth of 10.74%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 75.4/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze NATCOPHARM.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentNATCOPHARM.BO demonstrates superior asset utilization.
Valuation Score
ModerateNATCOPHARM.BO shows balanced valuation metrics.
Growth Score
ExcellentNATCOPHARM.BO delivers strong and consistent growth momentum.
Financial Health Score
ExcellentNATCOPHARM.BO maintains a strong and stable balance sheet.
Profitability Score
ModerateNATCOPHARM.BO maintains healthy but balanced margins.
Key Financial Metrics
Is NATCOPHARM.BO Expensive or Cheap?
P/E Ratio
NATCOPHARM.BO trades at 11.25 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NATCOPHARM.BO's PEG of 9.38 indicates potential overvaluation.
Price to Book
The market values NATCO Pharma Limited at 2.03 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 8.56 times EBITDA. This is generally considered low.
How Well Does NATCOPHARM.BO Make Money?
Net Profit Margin
For every $100 in sales, NATCO Pharma Limited keeps $34.13 as profit after all expenses.
Operating Margin
Core operations generate 39.89 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.08 in profit for every $100 of shareholder equity.
ROA
NATCO Pharma Limited generates $14.93 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
NATCO Pharma Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
NATCO Pharma Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
NATCOPHARM.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
11.25
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
9.38
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.03
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.84
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.10
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.15
vs 25 benchmark
ROCE
Return on capital employed
0.21
vs 25 benchmark
How NATCOPHARM.BO Stacks Against Its Sector Peers
| Metric | NATCOPHARM.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 11.25 | 29.45 | Better (Cheaper) |
| ROE | 20.08% | 779.00% | Weak |
| Net Margin | 34.13% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.03 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 4.10 | 4.65 | Strong Liquidity |
| ROA | 14.93% | -19344.00% (disorted) | Strong |
NATCOPHARM.BO outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews NATCO Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
135.70%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
316.71%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
314.12%
Industry Style: Defensive, Growth, Innovation
High Growth